Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
M SoteloT Alonso-GordoaP GajateE GallardoR Morales-BarreraJ L Pérez-GraciaJ PuenteP SánchezD CastellanoIgnacio DuranPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
Patients who achieved an objective response on atezolizumab presented a longer median duration of response and numerically superior 12 month survival rates when compared with chemotherapy responders along with a more favorable safety profile. PD-L1 expression did not discriminate patients who might benefit from atezolizumab.
Keyphrases
- locally advanced
- squamous cell carcinoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rectal cancer
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- clinical trial
- high grade
- phase ii study
- patient reported outcomes
- young adults
- free survival
- open label
- study protocol